H&O Biosis announced on the 30th of last month that a new drug substance under development was observed to have the effect of preventing the metastasis of liver cancer cells and inhibiting new blood vessels, which is a pathway for cancer cell proliferation. (Yakup.com)

'Natural herbal complex anticancer drug' inhibits liver cancer metastasis and new blood vessels

H&O Biosis announced on the 30th of last month that a new drug substance under development was observed to have the effect of preventing the metastasis of liver cancer cells and inhibiting new blood vessels, which is a pathway for cancer cell proliferation. Yakup.com
H&O BIOSIS (CEO Ki-woong Hyun and Jong-min Park) announced on the 30th of last month that a new drug substance under development was observed to have the effect of preventing the metastasis of liver cancer cells and inhibiting new blood vessels, which is a pathway for cancer cell proliferation.
H&O BIOSIS announced the results of a study last year that it had apoptosis and proliferation inhibitory effects on liver cancer cell lines and through additional tests afterwards, it had obtained these results.
According to the company, the candidate substance under development in this in-vitro experiment was confirmed to have metastasis inhibition and angiogenesis inhibitory effects on two liver cancer cell lines: Huh-7, a representative liver cancer cell line, and SNU-475, a resistant liver cancer cell line.
In addition, if this new drug passes the clinical trial, it will be the first treatment that has all the necessary functions for liver cancer treatment. As it is an oriental medicine material that does not have toxicity or drug resistance unlike existing treatments, it is expected that patients who were dependent on physical treatments such as liver transplantation will have an opportunity to experience a painless treatment process, the company explained.
Based on the in-vitro test conducted this time, H&O BIOSIS plans to confirm the efficacy in a non-clinical animal test and afterwards proceed to conduct a clinical trial with the goal of having phase 2 IND by the Ministry of Food and Drug Safety approved. H&O BIOSIS has also applied for a patent for the material.
Park Jong-min, CEO, who is responsible for the development of the natural complex anticancer drug, said, “Cell death and proliferation inhibition along with confirming metastasis and angiogenesis inhibition in this evaluation is an encouraging result” and “Considering the characteristics of low toxicity and side effects in the combined natural products, the validity and success potential of subsequent animal testing results will increase”.
CEO Park expressed his ambitions, saying “We will establish ourselves as forerunners in the development of next-generation anticancer drugs that go beyond the immuno-oncology drugs currently used for liver cancer treatment, and grow into the No. 1 company with a high success rate among the current liver cancer treatment market which has a low treatment rate”.